Everolimus plus lonafarnib for children with progeria
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether adding everolimus to ongoing lonafarnib improves health and slows complications in people with genetically confirmed progeria. It mainly checks safety and early signs of benefit in Phase I/II.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have genetically confirmed progeria confirmed by testing
- You are showing clinical signs of progeria, as the study team judges
- You are currently taking lonafarnib under the Boston protocol 09-06-0298
- You must be able to travel to Boston for study visits and tests
- You have not had serious (grade 3 or 4) side effects in the last 2 months
- You must not have had a major fracture or major surgery in the last 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This early-phase study tests how a medicine called rapalog affects the body in generally healthy middle-aged adults. It may help researchers understand safety and dosing, but it’s not meant to treat an existing disease.
This study tests whether a pill called everolimus can help improve social abilities in people with PTEN gene changes. Participating may help you or your child gain better social functioning, and the study provides close monitoring.
This trial tests a pill called everolimus to see if it can shrink or control abnormal blood vessel growths (vascular anomalies) that have not responded to other treatments. It may offer a new option for patients aged 1 year and older.
This trial tests a drug called everolimus for people with advanced colorectal cancer that has a specific change in a gene called CDK12. It aims to see if this drug can slow down the cancer when other treatments have stopped working.
This trial is testing a drug called alpelisib for people with PROS (a rare condition that causes parts of the body to grow too much). The drug targets a specific gene change (PIK3CA mutation) that is often the cause. If you have this condition and it's causing serious symptoms, this study might help shrink or slow the overgrowth, improving your quality of life.
Hear when a new Progeria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.